Top 50 Medical Startup Investors in United Kingdom (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Parkwalk Advisors
VC Fund
|
24 | United Kingdom, United States, Philippines | Seed, Series A, Series B | Biotechnology, Health Care, Software | $982k–$46M |
|
Scottish Enterprise
VC Fund
|
23 | United Kingdom, United States, Japan | Seed, Grant | Biotechnology, Software, Health Care | $104k–$4.1M |
|
UK Innovation & Science Seed Fund
VC Fund
|
22 | United Kingdom, United States | Seed, Series A | Biotechnology, Health Care, Medical | $393k–$14M |
|
Deepbridge Capital
VC Fund
|
21 | United Kingdom, Australia, Singapore | Seed, Series A | Health Care, Biotechnology, Medical | $152k–$15M |
|
Oxford Science Enterprises
VC Fund
|
18 | United Kingdom, United States, Finland | Seed, Series A, Series B | Health Care, Biotechnology, Software | $1.3M–$168M |
|
Archangels
VC Fund
|
16 | United Kingdom, United States | Seed, Series A | Software, Biotechnology, Health Care | $1.3M–$8.3M |
|
Oxford Technology Management
VC Fund
|
15 | United Kingdom, United States | Seed, Series A | Biotechnology, Health Care, Software | $33k–$7.9M |
|
SOSV
VC Fund
|
15 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
Scottish Investment Bank
VC Fund
|
14 | United Kingdom, United States, France | Seed, Series A | Software, Biotechnology, Health Care | $327k–$7M |
|
Mercia Fund Managers
VC Fund
|
13 | United Kingdom, United States, Hungary | Seed, Series A | Software, Health Care, Biotechnology | $196k–$14M |
|
Northstar Ventures
VC Fund
|
12 | United Kingdom, United States, Indonesia | Seed, Series A | Software, Health Care, E-Commerce | $39k–$9.7M |
|
Development Bank of Wales
VC Fund
|
12 | United Kingdom, Australia, United States | Seed, Debt Financing | Software, Health Care, Biotechnology | $18k–$3.7M |
|
Cambridge Innovation Capital
VC Fund
|
12 | United Kingdom, United States, Ireland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2M–$73M |
|
Jonathan Milner
Angel
|
12 | United Kingdom, United States, Spain | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $537k–$56M |
|
GM&C Life Sciences Fund
VC Fund
|
12 | United Kingdom, Italy, Germany | Seed, Series A | Health Care, Biotechnology, Medical | $65k–$4.1M |
|
Catapult Ventures
VC Fund
|
11 | United Kingdom, United States, Israel | Seed, Series A | Health Care, Biotechnology, Medical | $150k–$26M |
|
AlbionVC
VC Fund
|
10 | United Kingdom, United States, France | Series A, Seed | Software, Information Technology, Health Care | $2.2M–$20M |
|
Newable Private Investing
VC Fund
|
10 | United Kingdom, United States | Seed, Series A | Software, Health Care, Biotechnology | $196k–$5.2M |
|
M Ventures
VC Fund
|
9 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
IP Group
VC Fund
|
9 | United Kingdom, United States, Australia | Seed, Series A | Health Care, Biotechnology, Therapeutics | $393k–$23M |
|
SFC Capital
VC Fund
|
9 | United Kingdom, United States, Canada | Pre-Seed, Seed | Software, Artificial Intelligence, Information Technology | $158k–$2.2M |
|
Wellcome Trust
VC Fund
|
8 | United States, United Kingdom, France | Grant, Series C | Biotechnology, Health Care, Medical | $1.3M–$127M |
|
Praetura Ventures
VC Fund
|
8 | United Kingdom, Ireland, Australia | Seed, Series A | Software, Information Technology, Health Care | $393k–$13M |
|
Oxford Capital
VC Fund
|
8 | United Kingdom, United States, France | Seed, Series A | Software, Health Care, Biotechnology | |
|
Nesta Ventures
VC Fund
|
8 | United Kingdom, United States | Seed, Series A | Biotechnology, Medical Device, Medical | $982k–$26M |
|
Empirical Ventures
VC Fund
|
8 | United Kingdom | Seed, Pre-Seed | Medical, Biotechnology, Medical Device | $917k–$5.2M |
|
Providence Investment Company Limited
VC Fund
|
8 | United Kingdom | Series B, Seed | Biotechnology, Biopharma, Medical | $1.9M–$26M |
|
Business Growth Fund
VC Fund
|
7 | United Kingdom, Ireland, United States | Series A, Private Equity | Software, Health Care, Information Technology | $3M–$21M |
|
Foresight Group
VC Fund
|
7 | United Kingdom, United States, Ireland | Private Equity, Seed | Software, Manufacturing, Health Care | $655k–$8.5M |
|
SIS Ventures
VC Fund
|
7 | United Kingdom | Seed, Series A | Biotechnology, Health Care, Medical | $1M–$19M |
|
Mercia Asset Management
VC Fund
|
7 | United Kingdom, United States | Series A, Seed | Software, Information Technology, Health Care | $524k–$13M |
|
Innovate UK
VC Fund
|
7 | United Kingdom, United States, Canada | Grant, Seed, Pre-Seed | Health Care, Biotechnology, Software | $65k–$6.7M |
|
SyndicateRoom
VC Fund
|
7 | United Kingdom, United States, India | Seed, Equity Crowdfunding | Health Care, Software, Medical | $244k–$2.6M |
|
Salica
VC Fund
|
7 | United Kingdom, Germany, United States | Seed, Series A, Secondary Market | Software, Health Care, Information Technology | $700k–$18M |
|
Calculus Capital
VC Fund
|
7 | United Kingdom, United States, Ireland | Series A, Seed | Biotechnology, Software, Medical | $2M–$18M |
|
Crista Galli Ventures
VC Fund
|
6 | United Kingdom, United States, Sweden | Seed, Pre-Seed, Series A | Health Care, Medical, Wellness | $655k–$14M |
|
Octopus Ventures
VC Fund
|
6 | United Kingdom, United States, Germany | Series A, Seed, Series B | Software, Health Care, Information Technology | $1.9M–$46M |
|
Tern
VC Fund
|
6 | United Kingdom, United States | Seed, Series A | Software, Information Technology, Medical | |
|
Eos
VC Fund
|
6 | United Kingdom, Ireland, United States | Seed, Series A | Biotechnology, Health Care, Medical | $1.3M–$47M |
|
Future Planet Capital
VC Fund
|
6 | United Kingdom, United States, Canada | Seed, Convertible Note | Biotechnology, Health Care, Software | $897k–$7.9M |
|
Oxford Investment Consultants LLP
VC Fund
|
6 | United Kingdom | Series A, Seed | Software, Health Care, Biotechnology | $982k–$33M |
|
Nina Capital
VC Fund
|
6 | United States, United Kingdom, Germany | Seed, Pre-Seed, Series A | Health Care, Artificial Intelligence, Software | $573k–$22M |
|
QUBIS
VC Fund
|
6 | United Kingdom, United States | Seed, Grant | Health Care, Medical, Biotechnology | $655k–$2.8M |
|
VentureFounders
VC Fund
|
5 | United Kingdom, United States | Series A, Series B | Health Care, Medical, Software | $643k–$25M |
|
Invest Northern Ireland
VC Fund
|
5 | United Kingdom, United States, Ireland | Grant, Seed | Health Care, Biotechnology, Medical | |
|
Kindred Capital
VC Fund
|
5 | United Kingdom, United States, Germany | Seed, Series A, Series B | Software, Biotechnology, Health Care | $1.5M–$73M |
|
Innovation Ulster
VC Fund
|
5 | United Kingdom, Ireland | Seed, Series A, Pre-Seed | Health Care, iOS, Sports | |
|
Co-FundNI
VC Fund
|
5 | United Kingdom, Ireland | Seed, Pre-Seed | Software, Health Care, Information Technology | |
|
Woodford Investment Management
VC Fund
|
5 | United Kingdom, United States, Ireland | Series B, Series A | Biotechnology, Health Care, Medical | |
|
Angels in MedCity
VC Fund
|
5 | United Kingdom, United States | Seed, Angel | Health Care, Biotechnology, Medical | $458k–$880k |
| Access all 1115 investors in United Kingdom Medical startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Philippines
Investor stats
- Total investments: 255
- Round size: Seed $982k–$4.7M; Series A $1.6M–$13M; Series B $2M–$46M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- Nozzle.ai — Award-winning Amazon analytics tools designed to provide FBA Amazon Sellers with unique customer insights. Try for Free.
- Phasecraft — Using disruptive theory to unlock the power of quantum computing
- Echion Technologies — Echion Technologies is a spinout from the University of Cambridge Engineering Department, using proprietary battery active materials to develop next-generation Li-ion batteries.
Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Seed, Grant
- Geography: United Kingdom, United States, Japan
Investor stats
- Total investments: 285
- Round size: Seed $300k–$3.4M; Grant $104k–$4.1M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- TileBio —
- Sentinel —
- Orbital Marine Power — Orbital Marine Power is an innovative Scottish engineering company focused on the development of a low-cost, predictable, scalable floating tidal technology.
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 130
- Round size: Seed $393k–$5.9M; Series A $2.9M–$14M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2014
Portfolio highlights
- NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
- Presymptom Health — Enabling Early Diagnosis for better infection & sepsis care. With faster, more accurate testing. Presymptom Health is a medtech company developing a portfolio of patented diagnostic tests that are both faster and more reliable than those available today. Accelerate diagnosis. Address antimicrobial resistance.
- Pencil Biosciences — Pencil Biosciences is pioneering the next generation of gene editing. We are developing a fully synthetic, RNA-guided platform designed to overcome the limitations of current technologies.
Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, Australia, Singapore
Investor stats
- Total investments: 82
- Round size: Seed $152k–$2.6M; Series A $2M–$15M
- Lead/follow: 74% lead, 26% follow
- Last fund: Likely still investing — raised $1.4M in 2022
Portfolio highlights
- upLYFT — upLYFT is working on the next generation of smart wearables to help with musculoskeletal issues related to aging. Also working with pro athletes to help sporting individuals train harder and break records.
- GeneralPractice.AI — General Practice. AI is an advanced, AI-powered platform designed to transform primary care and general practice by streamlining clinical workflows, enhancing patient engagement, and reducing administrative burdens for healthcare professionals. It aims to revolutionize primary care by harnessing artificial intelligence to improve both clinical andadministrative aspects of general practice, ultimately delivering more efficient, personalized, and effective healthcare.
- Spotlight Pathology — Spotlight Pathology develops decision support tools powered by artificial intelligence (AI) to help in the diagnosis of blood cancers.
Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Finland
Investor stats
- Total investments: 161
- Round size: Seed $1.3M–$10M; Series A $5M–$46M; Series B $8.5M–$168M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $327M in 2022
Portfolio highlights
- Mode Labs — Mode Labs provide robust, continuous, and remote real-time chemical sensors.
- Amber Therapeutics — Developing intelligent bioelectrical therapies that can adapt, respond and learn from each person's individual physiology
- Pepgen — PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides,and they are advancing novel conjugate therapeutics to the clinic.
Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 84
- Round size: Seed $1.3M–$3.9M; Series A $1.6M–$8.3M
- Lead/follow: 54% lead, 46% follow
Portfolio highlights
- 1inhaler — 1inhaler operates as a developer of drug delivery device.
- BioCaptiva — BioCaptiva develops liquid biopsy technology devices to diagnose and monitoring to detect cancers.
- Administrate — Administrate is a comprehensive, configurable training management platform that helps organizations streamline enterprise learning and development. Organize, deliver, plan, automate, analyze, and scale your training program effectively -- all through one system. Deliver multi-modality learner experiences, maximize training resources, anddemonstrate business results with insight-rich reporting. Hundreds of organizations serving millions of learners choose Administrate to manage their training program.
Oxford Technology's SEIS fund and EIS fund enable private investors to access high growth technology startup opportunities and support UK innovation. SEIS and EIS tax reliefs offer downside protection, whilst gains can be tax free.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 107
- Round size: Seed $33k–$2.1M; Series A $786k–$7.9M
- Lead/follow: 7% lead, 93% follow
- Last fund: May invest from a new fund soon — last raise in 2012
Portfolio highlights
- OrganOx — OrganOx Limited was founded in 2008 to exploit normothermic preservation technology invented by Prof Peter Friend and colleagues and further developed by Prof Constantin Coussios at the University of Oxford.
- CryoLogyx — CryoLogyx Ltd. trading as CryoLogyx registered in England and Wales 13078280. VAT registered 373846855. Our registered office address is CryoLogyx Ltd, The Venture Centre, Sir William Lyons Road, Coventry, CV4 7EZ.
- Metacarpal — Metacarpal design upper-limb prosthetics without compromise. We aim to make the most robust, functional hand prosthesis that people love wearing because it works so effectively and looks so beautiful. Be proud to show your artificial side!
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Speak with our Entrepreneurship and Investment teams, who can help you find sources of finance, engage with funders and secure investment to grow your business.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 208
- Round size: Seed $327k–$3.1M; Series A $1.6M–$7M
- Lead/follow: 11% lead, 89% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
- IOTech — Discover IOTech Systems. Deploy, manage, and scale AI-driven, data-rich industrial systems at the edge with our open edge data platform.
- Administrate — Administrate is a comprehensive, configurable training management platform that helps organizations streamline enterprise learning and development. Organize, deliver, plan, automate, analyze, and scale your training program effectively -- all through one system. Deliver multi-modality learner experiences, maximize training resources, anddemonstrate business results with insight-rich reporting. Hundreds of organizations serving millions of learners choose Administrate to manage their training program.
Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Hungary
Investor stats
- Total investments: 133
- Round size: Seed $196k–$2M; Series A $2M–$14M
- Lead/follow: 67% lead, 33% follow
- Last fund: May invest from a new fund soon — last raise in 2013
Portfolio highlights
- 4D Medicine —
- Adludio — Adludio is the AI-powered platform that delivers interactive mobile advertising. By using data to design your ad creative, and algorithms to optimize your campaigns, Adludio makes sure you win the battle for brand attention.
- Role Mapper Technologies — Automate and transform how you design and manage job descriptions across your organisation. Hire, retain and grow an inclusive and diverse workforce with AI powered Intelligent Job Design.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Northstar Ventures invests venture capital in early and later stage, high growth companies tackling global challenges, focusing on climate tech and healthy ageing.
Show more...Investment focus
- Industry: Software, Health Care, E-Commerce
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Indonesia
Investor stats
- Total investments: 189
- Round size: Seed $39k–$1.8M; Series A $851k–$9.7M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- H2CHP — H2CHP's Free Piston Engine Technology enables your transition to green energy with the reliability & confidence of fuel flexibility.
- NunaBio — NunaBio operates as a privately-owned specialist DNA development company. NunaBio engaged in CRO (Contract Research Organizations) and CDMO (Contract Development and Manufacturing Organisation) activities.
- Moralbox —
Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Debt Financing
- Geography: United Kingdom, Australia, United States
Investor stats
- Total investments: 211
- Round size: Seed $327k–$3.7M; Debt Financing $18k–$2M
- Lead/follow: 58% lead, 42% follow
- Last fund: May invest from a new fund soon — raised $25M in 2018
Portfolio highlights
- Forth — Forth are a group of clinical and digital experts who are passionate about healthcare. They’re part of a new breed of digital healthcare companies who are transforming people’s relationship with their health by using technology to give them more information and help them gain greater control.
- enModus — Experience the thrill of competing against other players in online casino tournaments! These events offer a unique opportunity to showcase your skills and
- Antiverse — Designing biologics for 100 challenging targets
As a team, we have a passion for science and its potential to drive change. Through our expertise and our position in one of the country's most powerful science and technology ecosystems, we're able to identify and support the most promising entrepreneurs in knowledge intensive businesses and help them achieve their vision.With our financial backing and expert guidance, we're excited to enable the pioneers in life sciences and deep tech to create world-leading companies whose unique ideas bring financial success and global impact.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 97
- Round size: Seed $3.9M–$23M; Series A $2M–$73M; Series B $8.5M–$65M
- Lead/follow: 36% lead, 64% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Immutrin — Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively andspecifically remove established amyloid fibrils.
- Trent AI — Trent AI creates AI applications and agent security management software. It aids in risk assessment and mitigation in systems utilizing autonomous or semi-autonomous software agents. The company's technology monitors agent activity across APIs, tools, and workflows. It continuously assesses security posture via iterative scanning andcontextual understanding of system architectures.
- Forefront RF — Forefront RF tunable duplexer technology expands the accessibility of all mobile devices by unlocking SDR capabilities in the RFFE front end.
Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Spain
Investor stats
- Total investments: 61
- Round size: Seed $537k–$16M; Series A $4.1M–$50M; Series B $1.6M–$56M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Nuclera — Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis. Nuclera has since grown to fifty-seven employees across two continents as the Company delivers on its founders’ vision to make biology accessible to everyone through desktop bioprinting. With desktop bioprinting, researchers and scientists will be empowered totake control of biology through streamlined access to a next-day supply of proteins and genes.
- 52 North Health — At 52 North we are developing fully-integrated clinical, AI and medical-device based systems.
- Constructive Bio — We place non-canonical amino acids at precise positions in proteins and peptides to create therapeutics with new properties, then manufacture them through fermentation.
The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, Italy, Germany
Investor stats
- Total investments: 33
- Round size: Seed $65k–$936k; Series A $1.8M–$4.1M
- Lead/follow: 67% lead, 33% follow
Portfolio highlights
- Maxwellia — A contraceptive pill, Lovima, is now available to buy without a prescription.
- Acea Health — Acea Health is a digital healthcare company developing an application called Flynotes - a new digital consent platform. Flynotes analyses a number of factors, including the patient’s background, to deliver personalised risks and benefits. Flynotes aims to be the go-to solution for consent in healthcare. .
- Nexus Labs (Surgical Teaching) — Nexus Labs is an interactive learning resource for medical students.
The team behind Catapult Ventures are among the most experienced venture capital investors in the UK.Their experience spans a range of sectors from healthcare and pharmaceuticals to luxury consumer brands, manufacturing and software, as well as all stages: from start-ups and pre-revenue IP developers to company floatation and billions of poundsin revenue. Their administration team is equally experienced with each member having more than 10 years experience in a venture capital environment.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Israel
Investor stats
- Total investments: 104
- Round size: Seed $150k–$5.6M; Series A $1.6M–$26M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Rinicare — Rinicare is Lancaster-based SME that offers innovative technology solutions for healthcare applications.
- Pickle Robot — We make robots that unload trucks without retrofitting the warehouse
- Anello Photonics — Anello Photonics is founded by pioneers in silicon photonics and inertial navigation. The patented Anello SiPhOG gyroscope offers an affordable mass-market sensor with true Optical Gyroscope performance. The company is headquartered in Silicon Valley and funded by leading venture capital firms.
AlbionVC supports visionary founders and technologies with long-term capital and scale-up know-how. Founded in 1996, it was amongst the first to back leading global success stories such as Booking.com, Egress, Quantexa and Oviva. With £1bn in AUM and over 100 exits successfully realised, it funds venture breakthroughs that drive real outcomes forfounders, investors and society. AlbionVC is the technology investment arm of Albion Capital Group, which is authorised and regulated by the Financial Conduct Authority. For more information please visit: https://albion.vc/
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Series A, Seed
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 159
- Round size: Seed $2.2M–$13M; Series A $3.8M–$20M
- Lead/follow: 42% lead, 58% follow
Portfolio highlights
- Oviva — Oviva is digitizing the treatment of type 2 diabetes and obesity through a unique behavior change platform.They have developed unique, personalised behaviour change programmes that combine smartphone app and learning portals to support dietitian-led behaviour change for conditions such as type 2 diabetes and complex obesity. Their approach allowspatients to achieve a better health outcome without having to attend clinic appointments, whilst saving health systems significant sums by preventing the development of complications related to these health conditions.Oviva was founded in 2013 and is based in London, England.
- uMotif — uMotif provides the most modern eCOA/ePRO and eConsent platform designed to power clinical and real-world research.
- Ophelos — Flexible repayments, with an empathetic approach. Discover how we can help you get debt-free on your terms and timescales.
Newable: Helping over 20,000 businesses thrive annually with tailored financial products, advice, and flexible workspace solution
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 103
- Round size: Seed $196k–$3.9M; Series A $1.3M–$5.2M
- Lead/follow: 22% lead, 78% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Zentraxa — NATURE ENGINEERED FOR PURPOSE Through millions of years of evolution, nature has found solutions to the most difficult problems. Inspired by the diversity of nature, we precision engineer bespoke biomaterials to meet the toughest challenges across
- Elemendar — Elemendar is building Artificial Intelligence that reads cyber threat reports by humans and turns them into industry-standard structured information.
- NuVision — NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at theUniversity of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 163
- Round size: Seed $2.4M–$21M; Series A $5.2M–$45M; Series B $15M–$100M
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- CellFE — We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
- UNISERS — Developing solutions for Universal Contamination Analysis. Working with cutting edge technologies to revolutionize contamination control.
- Polaris Electro-Optics — Polaris Electro-Optics empowers integrated photonics for communications and computation.
IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Therapeutics
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Australia
Investor stats
- Total investments: 188
- Round size: Seed $393k–$7.6M; Series A $2M–$23M
- Lead/follow: 21% lead, 79% follow
- Last fund: May invest from a new fund soon — raised $125M in 2014
Portfolio highlights
- Lumai — Lumai delivers optical compute for the inference era, enabling up to 50x AI performance and 90% less power. Supports billion-parameter LLMs today.
- AudioScenic — THE NEW DIMENSION IN SOUND
- Intrinsic Semiconductor Technologies — Exciting new developments around the Internet of Things, Big Data, autonomous vehicles, and Artificial Intelligence highlight how our approach to computation must fundamentally change.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Discover the UK's leading SEIS Fund, offering tax-efficient investments in innovative startups. Join thousands of savvy investors and raise capital for your business with SFC Capital.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed
- Geography: United Kingdom, United States, Canada
Investor stats
- Total investments: 330
- Round size: Seed $159k–$2.2M; Pre-Seed $158k–$840k
- Lead/follow: 42% lead, 58% follow
- Last fund: May invest from a new fund soon — raised $1.9M in 2019
Portfolio highlights
- Elaitra — Elaitra’s breast cancer platform includes a Generative LLM for voice-based patient engagement, and a unique AI reading tool that helps doctors read 3D X-Rays. Operating in USA & UK. FDA 510(k) and UK regulator approved.
- Sages — Biodegradeable, non-polluting, low-impact and vibrant dyes extracted from food waste.
- WeFindFlats — Live and work anywhere, without housing worries.
Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Grant, Series C
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 115
- Round size: Grant $1.3M–$8M; Series C $10M–$127M
- Lead/follow: 37% lead, 63% follow
- Last fund: May invest from a new fund soon — raised $319M in 2018
Portfolio highlights
- Cultivarium — We develop molecular, hardware and software tools to accelerate the adoption of microbes for beneficial biotechnologies.
- Lario Therapeutics — Lario Therapeutics is a biopharmaceutical firm that develops precision therapeutics for epilepsy and neurological disorders.
- Ineffable Intelligence — Ineffable Intelligence develops machine learning systems that learn through interaction and experience. The company works on reinforcement learning approaches that allow models to improve by trial and error rather than relying on large human-generated datasets. Its core work centers on building a “superlearner,” a system designed to generateknowledge and skills by engaging with simulated or real environments.The organization develops algorithms and computational frameworks that support autonomous learning, experimentation, and decision-making processes. Its efforts involve designing AI models that can adapt, refine behavior, and solve complex problems through continuous feedback loops. The company’s research aims to expand how AI systems acquire knowledge and apply it across different domains.
Praetura Ventures has been supporting entrepreneurs with more than money since 2011. Click to find out more about how we can help businesses and investors.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A
- Geography: United Kingdom, Ireland, Australia
Investor stats
- Total investments: 129
- Round size: Seed $393k–$4.6M; Series A $1.7M–$13M
- Lead/follow: 77% lead, 23% follow
Portfolio highlights
- Peak — Accelerating AI adoption in retail and manufacturing, driving growth through inventory optimisation, AI-driven pricing, and more.
- Transreport — Transreport is a technology company, specializing in improving customer experience using technologies such as internet of Things.
- Patchwork — NHS workforce solution for managing rotas, bank shifts, and staffing. Trusted by 200+ organisations. Built by healthcare professionals.
Helping individuals and institutions invest in Venture Capital, Infrastructure and Media companies since 1999.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 141
- Lead/follow: no public data
Portfolio highlights
- Egregious — Egregious is an advanced research & intelligence lab established to defend humans from AI and provides narrative intelligence solutions across the public and private sectors to protect organisations and online users from malign influence using AI-driven data acquisition, insights, and engagement.
- Arcube — We make sure all travellers, frequent and infrequent, make the most of travel loyalty programs, using our data-driven approach, airlines can understand their customers and provide hyper-personalised offerings to boost value and retention.Arcube uses a data-driven approach to make the most of airline loyalty programs for both frequent andinfrequent flyers. Our software allows airlines to understand their customers and provide hyper-personalised offerings to boost value and retention at no extra cost to the airline.
- FinCrime Dynamics — Our mission is to help make the world’s financial system safer through rapid deployment of effective AI for financial crime analytics, enabled by enriched synthetic data that captures the dynamics of fraud and money laundering and loads them into tailor-made scenarios that explore diverse threats that financial organisations are exposed to.Thisgoal has taken us to the forefront of Synthetic Data and Fincrime Analytics, and we are proud to have in our team people that have helped shape the state-of-the-art of these fields.Keywords: Finacial services, AML, Synthetic Data, Fintech, Machine learning, Big data, Simulation, Fraud Analytics, Compliance
We bring bold ideas to life to change the world for good.
Show more...Investment focus
- Industry: Biotechnology, Medical Device, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 72
- Round size: Seed $982k–$2.2M; Series A $1.5M–$26M
- Lead/follow: 10% lead, 90% follow
- Last fund: May invest from a new fund soon — raised $34M in 2014
Portfolio highlights
- Citymart — Citymart powers cities to deliver services that work. Following best practices developed with leading cities around the world, Citymart connects cities and revolutionizes the way cities frame needs, complete procurements, and improve service delivery. Over 100 cities in 35 countries have adopted Citymart tools and methods to-date.
- Featurespace — Featurespace™ is the world leader in Enterprise Financial Crime prevention for fraud and Anti-Money Laundering. Featurespace invented Adaptive Behavioral Analytics and Automated Deep Behavioral Networks, both of which are available through the ARIC™ platform, a real-time machine learning software that risk scores events in more than 180 countriesto prevent fraud and financial crime.ARIC™ Risk Hub uses advanced, explainable anomaly detection to enable financial institutions to automatically identify risk, catch new fraud attacks and identify suspicious activity in real-time. More than 30 major global financial institutions are using ARIC to protect their business and their customers. Publicly announced customers include HSBC, TSYS, Worldpay, NatWest, Contis, Danske Bank, ClearBank, Akbank and Permanent TSB.
- Radio Physics Solutions — PASAR123 merupakan landasan utama bandar slot nomor 1 di indonesia memiliki fasilitas slot deposit pulsa tanpa potongan penarikan sangat mudah dan cepat.
Empirical Ventures supports innovative approaches to critical problems in the fields of biotechnology and life sciences.
Show more...Investment focus
- Industry: Medical, Biotechnology, Medical Device
- Stage:Seed, Pre-Seed
- Geography: United Kingdom
Investor stats
- Total investments: 25
- Round size: Seed $917k–$5.2M; Pre-Seed $1.1M–$1.6M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- Fermtech — Fermtech provides equipment for precision fermentation companies to scale production processes. Fermtech was founded in 2022 and was headquartered in Oxford, England.
- EnsiliTech — EnsiliTech is a biotechnology start-up developing ensilication, a platform technology, to remove the need for refrigeration when transporting and storing vaccines and biologicals
- HotGreen Solutions — HotGreen Solutions is an industrial high-temperature heat pump company providing process heat from electricity.
Providence Investment Company
Show more...Investment focus
- Industry: Biotechnology, Biopharma, Medical
- Stage:Series B, Seed
- Geography: United Kingdom
Investor stats
- Total investments: 12
- Round size: Series B $1.9M–$26M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- evonetix — evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniqueswe are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.
- DefiniGEN — Generate metabolic disease phenotypes in primary-like human cells using the best-in-class human iPSC differentiation platform. Find out more here!
- CellCentric — CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.
BGF is the most active equity investor in the UK and Ireland, providing long-term, minority investment to growing companies.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series A, Private Equity
- Geography: United Kingdom, Ireland, United States
Investor stats
- Total investments: 292
- Round size: Series A $3M–$21M; Private Equity $6.5M–$20M
- Lead/follow: 83% lead, 17% follow
- Last fund: Likely still investing — raised $102M in 2022
Portfolio highlights
- Camino — Camino Leisure Holdings is a Spanish bar and restaurant that serves authentic food and wines.
- Forefront RF — Forefront RF tunable duplexer technology expands the accessibility of all mobile devices by unlocking SDR capabilities in the RFFE front end.
- Snipple Animation Studios — Snipple are specialists in animated television and sports entertainment. We are one of the largest animation partners to Disney and Warner Brothers. We develop original IP and we have unique partnerships with sports teams, growing the fans of the future.
Foresight Group is a listed infrastructure and private equity investment manager which has been managing funds on behalf of institutions and retail clients for more than 35 years. Foresight has over £7.2 billion of assets under management across a number of funds on behalf of some of the world’s largest institutional investors, family offices,private and high net-worth individuals and retail investors. Foresight's investment strategies are underpinned by a strong environmental, social & governance (“ESG”) focus, which increasingly meets the demands of today’s investors and ensures we are consistently working towards creating a sustainable legacy for future generations.
Show more...Investment focus
- Industry: Software, Manufacturing, Health Care
- Stage:Private Equity, Seed
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 188
- Round size: Seed $655k–$5.2M; Private Equity $2.1M–$8.5M
- Lead/follow: 66% lead, 34% follow
Portfolio highlights
- ONFAB — ONFAB is a world leader in flexible pharmaceutical containment and high potent isolator solutions for the life sciences.
- Ruleguard — Ruleguard is an regulatory technology platform for financial sector firms that helps you manage and evidence compliance across your organisation. Features include automated horizon scanning, rules mapping, SMCR compliance, third party oversight tools, breach management and regulatory checklists.
- Biotherapy Services — Biotherapy Services is a specialist pharmaceutical biotech company. We use state-of-the-art technology and patented proprietary processes, working to GMP (Good Manufacturing Practice) pharmaceutical manufacturing standards, to produce a range of clinically safe and effective autologous biotherapies for a broad range of clinical conditions.
SIS Ventures has been created with the overall aim of supporting and growing high impact organisations through access to mission-aligned investment. SIS Ventures has a goal of becoming the go to investor and partner for social entrepreneurs. The fund will offer conventional financial returns alongside social and/or environmental returns byinvesting either equity or debt into purpose driven companies.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 33
- Round size: Seed $1M–$5.2M; Series A $2.8M–$19M
- Lead/follow: 3% lead, 97% follow
- Last fund: May invest from a new fund soon — raised $1M in 2018
Portfolio highlights
- Dxcover — Dxcover are a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life.
- MiAlgae — MiAlgae is a new-age microalgal production company that aims to revolutionize the £340 billion global livestock feed industry by producing microalgal products – through the remediation of wastewater – as nutrient supplements for fishmeal in livestock feeds. Their microalgal products are high in omegas and proteins, both of which are required forthe production of many livestock feeds, especially in the aquaculture sector.Their production methodology uses circular economy to reduce the operating costs involved in the production of microalgae and as such allows them to compete with other supplements currently on the market.
- Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Series A, Seed
- Geography: United Kingdom, United States
Investor stats
- Total investments: 101
- Round size: Seed $524k–$3.1M; Series A $2.2M–$13M
- Lead/follow: 61% lead, 39% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Netacea — Netacea takes a smarter approach to bot management. Intent Analytics™ powered by machine learning quickly and accurately distinguishes bots from humans to protect websites, mobile apps and APIs from automated threats while prioritising genuine users. Actionable intelligence with data-rich visualisations empowers you to make informed decisions aboutyour traffic. The Netacea approach offers incredible speed, accuracy and transparency, solving the growing problem of credential stuffing and account takeover at scale. The technology is designed to complement existing controls such as WAF rulesets, rate limiting and threat databases to provide a deep analysis of all website visitors, actionable intelligence and real-time threat.The Netacea approach continuously monitors your web traffic to pinpoint the difference in automated bot activity vs genuine visitors, keeping you ahead of evolving bot threats. Choose to automatically block, redirect or challenge automated attacks in real-time, or receive alerts notifying you of potential threats. With access to rich dashboards and data, you can easily identify and stop account takeover attempts early in the attack chain.Learn more at www.netacea.com
- Semble — The integrated clinical system for managing your patients' medical data and admin tasks.
- Locate Bio — Locate Bio is a regenerative medicine development company focused on orthobiologics. Locate Bio exists to help surgeons improve the lives of people with debilitating spinal conditions. We are curious about what is possible, but ground all our work in robust scientific evidence. We relentlessly pursue high-value opportunities with clear unmetclinical needs.
Innovate UK is part of the UK Research and Innovation .
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Grant, Seed, Pre-Seed
- Geography: United Kingdom, United States, Canada
Investor stats
- Total investments: 429
- Round size: Seed $367k–$6.7M; Grant $89k–$2.2M; Pre-Seed $65k–$1.3M
- Lead/follow: 80% lead, 20% follow
Portfolio highlights
- Ionech — Ionech harnesses natural energy sources to generate clean, reliable power through sustainable technologies. These solutions cut reliance on conventional energy, promoting a greener future.
- Voxelo.ai — Turn simple product videos into realistic, interactive and embeddable 3D models. Just Capture, Create and Convert with Voxelo - a new type of 3D & AI Studio.
- Your FLOCK — Your FLOCK helps teams stay together longer by increasing employees engagement by asking the right questions based on a team member's values.
SyndicateRoom is fintech company made up of data-scientists, investment professionals, software developers and marketers with one mission: to be an early investor in every British startup success story.To do this – and make fund investors money – we don’t try to spot the next Big Thing.Instead, we apply a data-driven model to portfolioconstruction; a repeatable process designed to maximise returns and minimise risk for fund investors. As such, we build startup portfolios that don’t attempt to predict the future; they work to stack the odds in investors’ favour.Our fund, Access EIS, aims to build investors a diversified portfolio of 50+ companies by co‑investing exclusively with some of the UK’s best-performing angel investors.
Show more...Investment focus
- Industry: Health Care, Software, Medical
- Stage:Seed, Equity Crowdfunding
- Geography: United Kingdom, United States, India
Investor stats
- Total investments: 133
- Round size: Seed $350k–$2.6M; Equity Crowdfunding $244k–$1.6M
- Lead/follow: 9% lead, 91% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Concr — Solving data to enable precision diagnostics for all.
- Xperiome — Match research-ready members to clinical and real-world studies, faster and smarter than ever before through data-driven insights into the rare disease experience.
- Net Zero Now — Net Zero Now adopts a sector based approach to making powerful climate action accessible to small and medium sized businesses. Working with the industry bodies, trade associations and larger corporates we start by creating a consistent sector protocol that defines what net zero means for businesses in that sector, offers guidance on how to getthere and a standard against which those that do, can be certified. We then configure our platform to enable businesses in the sector to go through the process in a simple way and offer this on subscription as SaaS. Our industry partners in each sector then provide a cost effective route to market, promoting a net zero solution to their members or customers. The approach aligns with all relevant global standards (GHG Protocol, SBTi, Oxford Principles) and has been endorsed by the UK Government Net Zero team. Andrew Griffith MP, the UK's Net Zero champion, is on record saying at COP26 "We love Net Zero Now"
Founded as an investment firm focusing on the most promising startups, we have evolved into a unique set of private market funds investing globally in equity and debt across complementary sectors and stages. We fuse traditional values with a contemporary approach and balance exacting processes with the agility to capture commercial opportunity andcompelling investment returns. Our continuous search for new opportunities has led us to create a balanced collection of complementary funds and relationships.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Series A, Secondary Market
- Geography: United Kingdom, Germany, United States
Investor stats
- Total investments: 189
- Round size: Seed $700k–$4.4M; Series A $5M–$18M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Abound — Fintern is a lending startup looking to offer an AI-driven alternative to costly payday loans. It aims to expand access to low-cost personal credit by using the UK’s new Open Banking standard to analyze consumers’ historical bank statement data. Open Banking data allows us to build a granular view of customers’ financial circumstances, properlyunderstand their affordability, and place less reliance on credit reference agency scores.The company was founded in 2020 and is based in London, United Kingdom.
- Semble — The integrated clinical system for managing your patients' medical data and admin tasks.
- Trade Ledger — Business lending technology for next-generation working capital that is customer centric, API-first, cloud-native and allows lenders to launch new products in 90 days.
At Calculus Capital they are specialists in creating and managing tax efficient private equity funds for the individual. Funds that are ideal for today's market - offering generous tax benefits, and significant growth potential within a sensible risk profile.They look to make £2-5 million investments in established companies with provenmanagement teams and a successful product or service. Their entrepreneurial flair, combined with their experience and sound commercial judgement has resulted in a diversified investment portfolio and an impressive track record. In June 2013 Calculus Capital was top ranked in the prestigious Martin Churchill Tax Efficient Review for the 6th year in a row. The Government has recently shown its support for EIS funds, by maintaining the five generous tax benefits and widening the scope of EIS investments. These changes benefit Calculus Capital's rigorous and proven strategy. As a result they are experiencing their strongest pipeline of prospective investments yet.
Show more...Investment focus
- Industry: Biotechnology, Software, Medical
- Stage:Series A, Seed
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 71
- Round size: Seed $2M–$18M; Series A $2.6M–$9.2M
- Lead/follow: 68% lead, 32% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- EnsiliTech — EnsiliTech is a biotechnology start-up developing ensilication, a platform technology, to remove the need for refrigeration when transporting and storing vaccines and biologicals
- Grateful — Grateful provides cashless tipping and trunk management software that integrates QR/NFC, EPOS systems, and compliance reporting.
- Laverock Therapeutics — Laverock Therapeutics is developing a gene silencing platform for the creation of programmable, allogeneic cell therapies.
Physician-led venture capital investing in TechBio, DeepTech Healthcare, and Digital Health.
Show more...Investment focus
- Industry: Health Care, Medical, Wellness
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, United States, Sweden
Investor stats
- Total investments: 36
- Round size: Seed $960k–$8.5M; Pre-Seed $655k–$2.5M; Series A $5.2M–$14M
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- Jude — Science-backed food supplement that makes you feel empowered, not embarrassed.
- Vitrue Health — At Vitrue Health, our mission is to reduce or eliminate the impact that musculoskeletal health issues have on over 40% of the population using cutting edge technology. We believe that the foundation of successful outcomes in musculoskeletal health, at every stage of the pathway, is accurate assessment. Whether it's a desk worker with early stages of neck pain or a patient having a total knee replacement, Vitrue's technology can help.
- Collective Minds Radiology — Collective Minds develops and delivers a cloud-based collaboration platform for healthcare and research with access to data, human and digital expertise.
We provide venture capital investment for the people, ideas and industries that will change the world. Learn about what we do and the kind of founders we back.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series A, Seed, Series B
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 357
- Round size: Seed $1.9M–$11M; Series A $3M–$21M; Series B $7.5M–$46M
- Lead/follow: 57% lead, 43% follow
- Last fund: May invest from a new fund soon — raised $101M in 2019
Portfolio highlights
- CertiVox — CertiVox solutions deliver simple, powerful information security to all things Internet (mainframes, too!), protecting business and individual privacy through the cloud and at rest. CertiVox was founded in 2009 to provide technology and services based on a simple belief: that everyone deserves the right to secure their information exchangessimply and easily. CertiVox's leading-edge encryption, key management and identity management solutions are currently in use at hundreds of the world’s leading corporations and used by individuals across the globe to protect their privacy.The companies passion is to create and share unique, cutting-edge cryptographic innovations for enterprise cloud computing and all things Internet. CertiVox are the only company in the global market today that has the technology in place to arm businesses and individuals with easy-to-use certificateless security solutions for any device and platform.Whether you are a business that wants to safeguard your company’s intellectual property, an ISV or SaaS provider that needs to embed cryptography and key management into your application, or an individual who wants to preserve the privacy of your personal data, CertiVox gives you the power to secure your information for all things Internet.CertiVox’s leading-edge solutions – including MIRACL (Multiprecision Integer and Rational Arithmetic C/C++ Library) Cryptographic SDK, on-demand encryption Key Management Service (KMS) and Identity Management Service (IDMS) – enable cloud service providers, independent software vendors (ISVs), communication providers, and smart device and semiconductor manufacturers to secure their voice and data communication solutions with ease.The PrivateSky Secure Information Exchange Service (SIX) gives individuals, businesses and their partners and customers easy-to-use tools to quickly encrypt email, files and documents without complex infrastructure or user burden. Compliance with mandatory encryption and privacy statues has never been easier.The bottom line: CertiVox's revolutionary certificateless cryptography, identity and key management solutions have taken the hassle out of Internet security, making it easy to securely exchange your information in any form, any time.
- Mojo — Join 600,000+ men worldwide using AI-powered coaches to build a performance mindset and take back control of their love lives.
- Phlux Technology — We develop, manufacture and supply innovative communication and vision components
Looking for an IoT investor for your start up or early stage company? Tern PLC is a venture capitalist working alongside ambitious entrepreneurs in the Internet of Things (IoT) space to deliver strategic IoT investment to grow your company.
Show more...Investment focus
- Industry: Software, Information Technology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 20
- Lead/follow: no public data
Portfolio highlights
- Konektio — Konektio is a dedicated M2M and IoT company which uses the best technology to deliver performance and solutions quickly and cost effectively. When you enquire we will need to visit you to discuss how to maximise the Konektio benefits for your particular business, whether OEM or End User, and also the type of devices (things) that you wish toconnect to. Our experience will help you to get the most out of any investment.
- FundamentalVR — Solutions for knowledge acquisition and skills development for any interactive medium
- Talking Medicines — Data Science for Life Sciences. Talking Medicines turns unstructured health data into actionable intelligence that proves real marketing impact.
Eos invests in, & commercialises, science & technology, from local seed-stage to global scale, with a focus on improving lives.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, Ireland, United States
Investor stats
- Total investments: 39
- Round size: Seed $1.3M–$6.1M; Series A $1.6M–$47M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- Dxcover — Dxcover are a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life.
- Neupulse — We are developing a wearable wrist device that delivers median nerve stimulation at the press of a button with the aim to give people control of their tics.
- Wobble Genomics — Wobble Genomics specializes in maximizing RNA and DNA sequencing efficiency for the discovery and detection of nucleic acid biomarkers.
Brilliant Ideas. Brilliant People. Brilliant Minds.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note
- Geography: United Kingdom, United States, Canada
Investor stats
- Total investments: 142
- Round size: Seed $897k–$7.9M
- Lead/follow: 7% lead, 93% follow
- Last fund: Likely still investing — raised $23M in 2022
Portfolio highlights
- Zentraxa — NATURE ENGINEERED FOR PURPOSE Through millions of years of evolution, nature has found solutions to the most difficult problems. Inspired by the diversity of nature, we precision engineer bespoke biomaterials to meet the toughest challenges across
- iFast Diagnostics — iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.
- Vitarka Therapeutics — Vitarka Therapeutics has engineered an intracellular drug delivery technology, EndoPore, using pore forming proteins for intracellular targets.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!xford Investment Consultants LLP ("OIC") advises Thompson Taraz, the Investment Manager of Oxford Technology and Innovations EIS Fund ("OTIF"). OIC is an Appointed Representative of Stoneware Captial LLP, which is authorized and regulated by the Financial Conduct Authority in the United Kingdom.The focus of OIC research ison University of Oxford spin out companies.Over the last fifteen years Oxford has produced a string of world-class spin-out companies. It is our belief that the next generation of world-class Oxford businesses is just waiting to be discovered.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Seed
- Geography: United Kingdom
Investor stats
- Total investments: 27
- Round size: Seed $982k–$7.6M; Series A $9.4M–$33M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Diffblue — Diffblue Testing Agent generates, verifies, and fixes unit tests autonomously across enterprise codebases.
- Panda Surgical — Panda Surgical is developing a next-generation handheld robotics platform that offers neurosurgeons enhanced dexterity and control in confined spaces, enabling more surgeons to perform complex minimally invasive procedures.
- Oxford Quantum Circuits — Oxford Quantum Circuits developing technology using the power of quantum to do things which have never been achieved before, from enabling life-changing drug discoveries to developing new battery technologies.
We deploy early stage capital to fuel the growth of need-driven health technology companies.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 81
- Round size: Seed $2M–$5.2M; Pre-Seed $573k–$2.4M; Series A $5M–$22M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
- io Health — Io Health Technologies LLC provides AI-driven tools for home health documentation and workflow automation in healthcare.
- Sober Sidekick — Gamified peer to peer support
Working with academic entrepreneurs, QUBIS Ltd has grown a portfolio of shareholdings in viable companies over 27 years that have succeeded on an international level.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Grant
- Geography: United Kingdom, United States
Investor stats
- Total investments: 28
- Round size: Seed $655k–$2.8M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- RETìníZE — RETìníZE is an AR, VR, multi-screen installations, and software development.
- Sonrai Analytics — Analyse complex biomedical data across omics, imaging, and clinical datasets to uncover insights and make confident drug-development decisions.
- Re-Vana Therapeutics — Re-Vana Therapeutics is a ocular pharmaceuticals & drug delivery company focused on the development and commercialisation of innovative long-acting, biodegradable drug delivery platforms to address ophthalmic conditions such as age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma and ocular infections.Their deliveryplatforms enable tailored delivery of therapeutics for long-term and can be administered by various routes to the eye. By using their platform technologies, delivery of a broad range of molecules including proteins, peptides, and small molecules can be achieved from 1 week to 1 year. The platform technologies are based on FDA-approved polymers.Their injectable platform, OcuLief™, can be tailored for the treatment of AMD and DR to achieve a long-term release of anti-vascular endothelial growth factors (anti-VEGF) or corticosteroids for 1-12 months. Their preformed platform, EyeLief™, can be tailored for the treatment of Glaucoma and retina diseases, to achieve a long-term release of small or large molecules for 6 months or more.The design strategy of Re-Vana revolves around increasing patient compliance by reducing pain and frequency of treatment, lowering side effects by controlled drug release, and cost saving for health care providers and pharmaceutical companies.
Volution is a UK based Venture Capital firm. We back ambitious Fintech and SaaS businesses, ready to accelerate their growth to Series B and beyond.
Show more...Investment focus
- Industry: Health Care, Medical, Software
- Stage:Series A, Series B
- Geography: United Kingdom, United States
Investor stats
- Total investments: 51
- Round size: Series A $643k–$9.8M; Series B $4.3M–$25M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Zopa — Zopa is a P2P money lending service that allows lenders and borrowers to deal directly with one another, cutting out the banks who act as middlemen. It works in the following way: the company first categorizes borrower credit grades with an A*, A, B, C, or Y rating; then lenders make offers that vary by money amount and time period for persons witha certain credit grade, and borrowers can then agree the aggregate offered rate.Zopa takes on such responsibilities as distributing money between parties, completing the legal paperwork, performing borrower identity/credit checks, and employing a collections agency that chases missed payments for the lender.Zopa also mitigates risk for lenders by enforcing monthly direct debit repayment, making borrowers sign a legal contract, and allowing lenders to lend small chunks of money to individual borrowers (i.e. someone lending £1000 would have their money spread across say, 100 borrowers).The company itself makes money by charging a fixed fee for borrowers and a 1% annual fee for lenders.Zopa has received public acclaim as well, having been awarded CNET Technology Awards' 2006 Internet Innovation of the Year, the 2007 Webby Award for Best Banking/Bill-Paying Website, the 2008 Webby Award for Financial Services, the Banker 2007 Award for Best Internet Project, and Moneywise 2009 Awards for Best Customer Service and Best Personal Loan.One of the three initial members of the UK's Peer-to-Peer Finance Association, together with FundingCircle and RateSetter. Other P2P lending services include
- DeadHappy — DeadHappy is an insurtech company that provides digital pay-as-you-go life insurance services. It specializes in offering flexible life insurance policies that are designed to be cheaper, easier, and better than existing traditional providers. Its offerings include pricing insurance based on current circumstances and the option to add furthercoverage on a rolling basis.The company was founded in 2013 and is headquartered in Leicester, England.
- Lightpoint Medical — Miniature, drop-in gamma probe system for minimally-invasive, robot-assisted cancer surgery.
Invest Northern Ireland is Northern Ireland's economic development agency. Their overall goal is to help create wealth for the benefit of the whole community by strengthening the economy and helping it grow.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Grant, Seed
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 33
- Lead/follow: no public data
Portfolio highlights
- TruCorp — TruCorp: Your source for lifelike Medical Training Equipment. Explore our intubation manikins & airway trainers. Request a free demo today!
- GoPlugable — GoPlugable's innovative approach to EV charger sharing makes it easier for businesses & individuals to access and share charging infrastructure.
- CV6 Therapeutics — CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases.
A new model for Venture Capital where every founder we back becomes a co-owner of the fund
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 108
- Round size: Seed $1.5M–$16M; Series A $7.9M–$33M; Series B $13M–$73M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Hofy — Use Hofy's equipment management platform to remotely supply, manage and maintain subscription workstations, while staying compliant.
- RobCo — Easily automate the repetitive tasks in your production facility with modular industrial robots from RobCo.
- Paddle — The revenue engine powering payments for n8n, Letterboxd & AdGuard. One platform that handles subscription billing, payments and compliance.
The wholly owned knowledge and technology venturing company of Ulster University.
Show more...Investment focus
- Industry: Health Care, iOS, Sports
- Stage:Seed, Series A, Pre-Seed
- Geography: United Kingdom, Ireland
Investor stats
- Total investments: 12
- Lead/follow: no public data
Portfolio highlights
- Axial3D — Leading the way with the latest 3D imaging, models, and devices
- RETìníZE — RETìníZE is an AR, VR, multi-screen installations, and software development.
- NeuroCONCISE — Innovative and stylish wearable neurotechnology for brainwave measurement and analysis. Neurotechnology, Biotechnology, Brain-Computer Interfacing, BCI, Flex EEG, EEG, Clinical Trials, Clinical Assessment Tools, Machine Learning, Prolonged Disorders of Consciousness Research, Research
Through Co-Fund NI £12.5million will be made available to invest alongside business angels and business angel syndicates (hereafter referred to as "private investors" or "syndicates") into eligible SME's based in Northern Ireland. When matched 45% public with 55% private investors on a deal-by-deal basis this will give anoverall "fund" size of £28m.This initiative is provided by Invest Northern Ireland and part-financed by the European Regional Development Fund under the Invest for Growth and Jobs Programme 2014-2020.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Pre-Seed
- Geography: United Kingdom, Ireland
Investor stats
- Total investments: 42
- Lead/follow: no public data
Portfolio highlights
- AMPLY Discovery — AMPLY Discovery is to develop new biological molecules for anti-infective health and nutrition applications in animal and human health.
- GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .
- Cumulus Neuroscience — Cumulus Neuroscience has created a next-generation integrated physiological and digital biomarker platform.
Woodford Investment Management is a privately owned investment firm manages equity mutual funds. At Woodford, they don’t want to be just another fund management company. They want to create something different and better for their investors and they feel strongly that existing and potential clients are entitled to understand what they are doingwith their money.As investors, they are active, engaged, long-term, disciplined, diligent and focused. That’s a lot of things to say about their selves but each word is important in helping you to understand how they manage money – they will explain in more detail as they move along.Their investment approach and process are focused on value discovery, not price discovery. They believe that financial markets are inherently inefficient and that, through disciplined and diligent analysis, they can identify investment opportunities where market prices do not reflect long-term fundamental value. By exploiting this pervasive market characteristic, they believe they can create real long-term value for their investors.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 63
- Lead/follow: no public data
Portfolio highlights
- Revolut — Join 40+ million customers globally using Revolut to send money to 160+ countries, hold up-to 36 currencies in app, spend in 150+ currencies, and manage their money.
- Atom Bank — Explore our savings accounts, mortgages and business loans in our digital banking app. Compare our savings rates and join the future of secure digital banking. FSCS protected.
- Evofem Biosciences — Lithera is developing products for aesthetic medicine to address both medical and lifestyle indications. Its lead product is an injectable treatment to achieve local, selective fat tissue reduction (pharmaceutical lipoplasty). Using FDA registered drugs proven safe and effective in other indications, its product targets and stimulates natural fatmetabolism and achieves non-ablative, non-surgical fat tissue reduction in specific locations.
Angels in MedCity is a partnership between MedCity, London Business Angels and Angels4LifeSciences. The programme aims to introduce new people to investing and investing in the healthcare/life sciences sector via investor workshops and introduce business angels to investment opportunities from highly-selected and trained companies.With aparticular focus on drug therapies, digital health and medical device technologies, Angels in MedCity brings potential investors together with life sciences experts in a programme aimed at both people who are new to investing and experienced investors who have little or no experience in the life sciences sector. The aim is to build investor understanding in the life sciences sector and support life sciences companies to gain funding to commercialise their ideas.Angels in MedCity has created a community of investors supported through a programme of investor workshops. Using case studies and tips from experienced investors in the field, the workshops explain how to identify and structure a good deal in the life sciences sector, as well as provide expert advice on tax breaks and legal issues.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Angel
- Geography: United Kingdom, United States
Investor stats
- Total investments: 18
- Round size: Seed $458k–$880k
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Atelerix — Discover Atelerix's hypothermic hydrogels for reliable cell preservation and ambient temperature shipping. Ensure fresh, viable cell samples.
- Clustermarket — The intuitive lab management system for all academic research facilities and industrial laboratories that need to efficiently manage equipment bookings.
- DynamX Medical — DynamX Medical has developed a reliable and inexpensive precancer screening system for rapid tissue biopsy analysis that can be operated point-of-care by nurses.
Medical Investor funding in United Kingdom at a glance
Stats across 1.2k deals from 1.1k investors.
Access all 1115 investors in United Kingdom Medical startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Medical Investors in United Kingdom investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 1115 investors investing in United Kingdom Medical startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!